Expert Opinion on Therapeutic Patents

Papers
(The median citation count of Expert Opinion on Therapeutic Patents is 5. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-06-01 to 2026-06-01.)
ArticleCitations
Recent developments of agents targeting Vibrio cholerae : patents and literature data62
The role of patent analysis in target selection49
FAK inhibitors in cancer, a patent review – an update on progress38
Update on mGlu4 modulator patents: 2017 to present36
Traf2- and Nck-interacting kinase inhibitors: a patent review (2008–2024)35
Targeting the EGFR/RAS/RAF signaling pathway in anticancer research: a recent update on inhibitor design and clinical trials (2020–2023)32
Progress with YAP/TAZ-TEAD inhibitors: a patent review (2018-present)32
RORγt inhibitors in clinical development for the treatment of autoimmune diseases: challenges and opportunities31
Recent advances in factor XII(a) inhibitors: an updated patent landscape (2020-present)31
Caspase inhibitors: a review on recently patented compounds (2016–2023)30
P2Y 12 R antagonists in antithrombotic therapy: a patent and literature review (2019–present)27
An updated patent review of AKT inhibitors (2020 – present)23
Patent review of cannabinoid receptor type 2 (CB 2 R) modulators (2016-present)23
A patenting perspective of fat mass and obesity associated protein (FTO) inhibitors: 2017–present23
A patent review of hepatitis B virus core protein allosteric modulators (2019-present)23
A patent review of MAPK inhibitors (2018 – present)22
Inhibition of GTPase KRAS G12D : a review of patent literature21
Proteolysis-Targeting Chimeras (PROTACs) targeting the BCR-ABL for the treatment of chronic myeloid leukemia – a patent review21
Antiprotozoal drugs: challenges and opportunities20
GPR120 agonists for the treatment of type 2 diabetes: an updated patent review (2020-present)20
Insights and trends in development of TEAD–YAP/TAZ inhibitors: a review of PCT patents (2022 to June 2025)20
Targeting the LPA1 signaling pathway for fibrosis therapy: a patent review (2010-present)20
A patent review of LPAR1 antagonists (2010 – present)18
Synthetic lethality: targeting the SMARCA2 bromodomain for degradation in SMARCA4-deficient tumors – a review of patent literature from 2019–June 202318
An update on PDGFR inhibitors: a patent review (2020 - present)18
Novel fatty acid amide hydrolase (FAAH) inhibitors: a patent review from 2015 to 202517
Small-molecule RNA ligands: a patent review (2018–2024)17
An updated patent review on PD-1/PD-L1 antagonists (2022-present)17
Therapeutic compounds targeting interleukin-1 receptor-associated kinase 4 (IRAK4): an updated patent review (2019 to present)17
A patent review of IDH1 inhibitors (2018-present)17
Recent advances in the development of P2Y 14 R inhibitors: a patent and literature review (2018-present)17
Phosphodiesterase 2 (PDE2) inhibitors: an updated patent review (2017–present)16
The challenging inhibition of Aldose Reductase for the treatment of diabetic complications: a 2019–2023 update of the patent literature16
A patent review of P2X7 receptor antagonists to treat inflammatory diseases (2018–present)16
The next generation of EGFR inhibitors: a patenting perspective of PROTACs based EGFR degraders16
Novel urate transporter 1 (URAT1) inhibitors: a review of recent patent literature (2020–present)16
A patent and literature review of CDK12 inhibitors15
A patent review of NLRP3 inhibitors for inflammatory diseases (2023-present)15
Antimalarial drugs: what’s new in the patents?15
An updated patent review of MALT1 inhibitors (2021–present)15
Biofilm and bacterial membrane vesicles: recent advances14
Part-II: an update of Schiff bases synthesis and applications in medicinal chemistry-a patent review (2016-2023)14
Trends in covalent drug discovery: a 2020–23 patent landscape analysis focused on select covalent reacting groups (CRGs) found in FDA-approved drugs14
Patent landscape and therapeutic evolution of mazdutide: a dual GLP-1/Glucagon receptor agonist for obesity and type 2 diabetes14
Small molecules targeting immune checkpoint proteins for cancer immunotherapy: a patent and literature review (2020–2024)13
A patent review of von Hippel-Lindau (VHL)-recruiting chemical matter: E3 ligase ligands for PROTACs and targeted protein degradation (2019–present)13
A patent review of NLRP3 inhibitors to treat autoimmune diseases13
Are patents important indicators of innovation for Chagas disease treatment?13
Sirtuin modulators: a review of patents from 2020 to 202413
Biomedical applications of prokaryotic carbonic anhydrases: an update13
Inhibition of nicotinamide phosphoribosyltransferase (NAMPT) in cancer: a patent review13
Drugs and nanoformulations for the management of Leishmania infection: a patent and literature review (2015-2022)13
An updated patent review of EZH2 inhibitors (2024–present)13
An updated patent review of GPR40/ FFAR1 modulators (2020 – present)12
The patent review of the biological activity of tropane containing compounds12
Implementation and outcomes of China’s drug patent linkage system: lessons from international experience12
An updated patent review on rational combinations of HDAC inhibitors for cancer chemotherapy (2020 – present): part 1-patent granted12
The management ofBabesia, amoeba and other zoonotic diseases provoked by protozoa12
Progress with polo-like kinase (PLK) inhibitors: a patent review (2018–present)12
An updated patent review of TRPA1 antagonists (2020 – present)12
Correction11
A patent review of histone deacetylase 8 (HDAC8) inhibitors (2013–present)11
Histamine H 3 receptor antagonists/inverse agonists: a patent review (October 2017 – December 2023) documenting progress11
An insight into the last 5-year patents on Porphyromonas gingivalis and Streptococcus mutans , the pivotal pathogens in the oral cavity11
5’-Ectonucleotidase (CD73) inhibitors: a patent review (2021-present)11
Small molecule ATM inhibitors as potential cancer therapy: a patent review (2003–present)11
Challenges, opportunities, and therapeutic potential of JAK inhibitors and their derived PROTACs (2022 – 2023)11
Protein tyrosine phosphatase inhibitors: a patent review and update (2012–2023)11
A patent review of BRD4 inhibitors (2020–present)11
A patent review of peptidylarginine deiminase 4 (PAD4) inhibitors (2014–present)10
An updated patent review of histone deacetylase (HDAC) inhibitors in cancer (2020 – present)10
A patent review of DNA polymerase theta (Polθ) targeted therapies (2019–2025)10
Impact of patent-granting differences between Japan and the United States on patent protection for medical methods: insights from genome editing patents10
A patent review of selective CDK9 inhibitors in treating cancer10
An updated patent review on rational combinations of HDAC inhibitors for cancer chemotherapy (2020 – present): part 2 - patent published9
An updated patent review of matrix metalloproteinase (MMP) inhibitors (2021-present)9
Dihydrofolate reductase inhibitors: patent landscape and phases of clinical development (2001–2021)9
Bruton’s tyrosine kinase (BTK) inhibitors: an updated patent review (2019–2024)9
An updated patent review of small molecule KCNT1 inhibitors (2022–2024)9
An updated patent review of isoflavones and isocoumarins (2018–2024)9
Rho kinase inhibitors: a patent review (2017–2023)9
A patent review of CXCR7 modulators (2019-present)9
A patent review on arachidonic acid lipoxygenase (LOX) inhibitors for the treatment of neurodegenerative diseases (2018-present)8
An updated patent review of rearranged during transfection (RET) kinase inhibitors (2022-present)8
Selective estrogen receptor degraders (SERDs) and covalent antagonists (SERCAs): a patent review (July 2021–December 2023)8
Helicase-primase inhibitors from Medshine Discovery Inc. (WO2018/127207 and WO2020/007355) for the treatment of herpes simplex virus infections – structure proposal for Phaeno Therapeutics drug candid8
Quorum sensing inhibitors (QSIs): a patent review (2019–2023)8
Patent landscape of small molecule inhibitors of METTL3 (2020-present)8
Type I inhibitors of tropomyosin receptor kinase (Trk): a 2020–2022 patent update8
Recent advances in the development of STING inhibitors: an updated patent review7
An updated patent review of Mcl-1 inhibitors (2020–2022)7
A patent review of xanthine oxidase inhibitors (2021–present)7
Therapeutic cysteine protease inhibitors: a patent review (2018–present)7
Recent advances on patents of Plasmodium falciparum dihydroorotate dehydrogenase ( Pf DHODH) inhibitors as antimalarial agents7
Patents involving monoamine oxidase (MAO): a comprehensive update (2022–2025) on its inhibitors and applications7
Conjugates of monocyclic β-lactams and siderophore mimetics: a patent evaluation (WO2023023393)7
An updated patent review on monoamine oxidase (MAO) inhibitors7
A patent perspective of antiangiogenic agents7
Nurr1 modulators – a patent review (2019–present)7
Synthetic lethality: targeting SMARCA2 ATPase in SMARCA4-deficient tumors – a review of patent literature from 2019–30 June 20237
Pitfalls in patenting academic CAR-T cells therapy7
Targeting the PI3K/AKT signaling pathway in anticancer research: a recent update on inhibitor design and clinical trials (2020–2023)7
Selective COX-2 inhibitors as anticancer agents: a patent review (2018-2023)7
A patent review of pharmaceutical and therapeutic applications of oxadiazole derivatives for the treatment of chronic diseases (2013–2021)7
An updated patent review of glutaminase inhibitors (2019–2022)6
Anticancer drugs: where are we now?6
A patent review of VEGFR-2 inhibitors: an update (2022 – present)6
The therapeutic potential of phosphodiesterase 9 (PDE9) inhibitors: a patent review (2018-present)6
A patent review of IDO1 inhibitors for cancer (2023 – present): an update6
An updated patent review of protein arginine N-methyltransferase inhibitors (2019–2022)6
Proteasome inhibitors as anticancer agents6
An updated patent review of BRD4 degraders6
Coactivator-associated arginine methyltransferase 1 (CARM1) inhibitors: a patenting perspective (2018-present)6
N-acetylgalactosamine delivery systems for RNA therapeutics: a patent perspective6
An updated patent review of stimulator of interferon genes agonists (2021 – present)6
A review of the patent literature surrounding TRPV1 modulators6
Mycobacterium tuberculosis inhibitors: an updated patent review (2021–present)6
A patent review of anti-coronavirus agents targeting the spike-ACE2 interaction (2019–present)6
Small molecule modulators of IL-17A/IL-17RA: a patent review (2013-2021)5
Tricyclic boronic acids as broad-spectrum serine and metallo-β-lactamase inhibitors with in vitro activity against Acinetobacter b5
Receptor-interacting protein kinase 1 (RIPK1) inhibitor: a review of the patent literature (2018-present)5
A patent review of cyclin-dependent kinase 7 (CDK7) inhibitors (2018-2022)5
Small molecule agonists of Toll-like receptors 7 and 8: an updated patent review 2021 – 20255
BET inhibitors: an updated patent review (2018–2021)5
A patent review of KDM4 histone demethylase inhibitors (2014-present)5
A patent review of CHK1 inhibitors (2019 – present)5
Novel therapeutic opportunities for Toxoplasma gondii, Trichomonas vaginalis, and Giardia intestinalis infections5
A patent review of galectin-1 and galectin-3 inhibitors and their potential therapeutic applications (2022-present): an update5
A patent review of MLKL modulators (2023 – present)5
Trispecific anti-CD3/BCMA/CD38 antibodies for multiple myeloma: a patent evaluation of US202401326155
Update on JNK inhibitor patents: 2015 to present5
CBL-B – An upcoming immune-oncology target5
Natural products as a source of new anticancer chemotypes5
0.11585593223572